NCT04009148Active, not recruiting
Cascade Testing in Families With Newly Diagnosed Hereditary Breast and Ovarian Cancer Syndrome
Source: ClinicalTrials.gov · Last updated 14 May 2026
Brief summary (registry, in English)
Identification of BRCA mutations in ovarian cancer patients may help guide cancer therapies, prognosis, post-operative screening, and other preventative treatments beyond the initial diagnosis. Likewise, genetic testing of ovarian cancer patients for these germline mutations provides invaluable information for families regarding cancer risk, genetic testing, and subsequently indication for risk-reducing surgery. Cascade testing provides a unique opportunity to identify carriers of a deleterious BRCA mutation which can allow for surgical and chemoprevention of prevention of ovarian cancer. There is currently no literature on the rates of referral for the family members.
- Status (registry)
- Active, not recruiting
- Study type
- Observational
- Enrollment
- 118 (actual)
- First submitted
- 2 Jul 2019
- Start date
- 1 Mar 2019
- Primary completion date
- 11 Jun 2025
- Lead sponsor
- NYU Langone Health
- Diseases
- Ovarian cancer
- NCT number
- NCT04009148
What you commit to
- Study type: Observational
- Participants enrolled: 118
- From 1 Mar 2019 to the primary completion date, 11 Jun 2025
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Other
- Subjects whose first and/or second degree relatives have already been tested with the subject's known mutations, and no other viable family members are available for testing.
Who the study is looking for
- All subjects must have a diagnosis of epithelial ovarian cancer, Fallopian tube caner or primary peritoneal cancer with a known pathogenic genetic mutation.
- All subjects must agree to participate.
- All subjects must have first or second degree relatives who have not been diagnosed with the same genetic mutation.
- A previous diagnosis of cancer in the subject's first or second degree relative is allowed.
Age in the registry: 18 years to 99 years · Sex: All · Accepts healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| NYU Langone Health Coordinator of this site? Confirm its status | New York | United States | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.